Core Viewpoint - Vanda Pharmaceuticals Inc. has received FDA approval for NEREUS (tradipitant), leading to a significant increase in stock price by 20.20% to $8.45 in after-hours trading, indicating strong market interest in the new therapy for motion-induced vomiting in adults [1]. Clinical Efficacy - NEREUS showed efficacy in three pivotal clinical trials, with vomiting rates in treated patients ranging from 10.4% to 19.5%, compared to 37.7% to 44.3% in placebo groups, achieving risk reductions of over 50% to 70% [2]. - The Motion Syros trial involved 365 patients, while the Motion Serifos study included 316 patients, both demonstrating statistically significant results (p < 0.0001 and p ≤ 0.0014 respectively) [2]. Adverse Reactions - Common adverse reactions reported included somnolence in 6% to 12% of patients and fatigue in 6% to 8% [3]. Market Potential - Approximately 25% to 30% of U.S. adults, estimated at 65 million to 78 million people, experience motion sickness, with 5% to 15% suffering from severe, recurrent symptoms, highlighting a substantial market opportunity for NEREUS [4]. Pipeline Development - Vanda is also advancing tradipitant for other indications, including gastroparesis and nausea/vomiting prevention related to GLP-1 receptor agonists, indicating a broader therapeutic potential [5]. Trading Metrics - Vanda Pharmaceuticals has a market capitalization of $415.45 million, with a 52-week high of $7.47 and a low of $3.81. The stock has gained 47.07% over the past 12 months, reflecting a strong long-term trend [6]. - The stock is currently trading at 88% of its 52-week range, suggesting bullish sentiment, although it is approaching overbought levels [6]. Price Action - On the previous trading day, the stock closed at $7.03, down 2.36%, but maintains strong momentum in the 90th percentile, indicating a positive price trend across all time frames [7].